BioCentury | Oct 15, 2012
Clinical News

Herceptin trastuzumab: Phase III data

Genentech Inc. , South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan F. Hoffmann-La Roche Ltd. (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Herceptin trastuzumab ( RG597 ) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2)...
BioCentury | Sep 27, 2004
Company News

Inyx, Phares Technology BV deal

...IYXI completed its acquisition of a platform technology from Phares subsidiary Phares Drug Delivery AG (Muttenz, Switzerland) that IYXI...
...substances to mucosal membranes. Financial terms were not disclosed. Inyx Inc. (IYXI), New York, N.Y. Phares...
BioCentury | May 6, 2002
Emerging Company Profile

Corporate Profile

...by Sanjay Kakkar, Canasta Group Ltd. and Thrombosis Research Institute Corporate partners: Covance Inc. , Phares...
Items per page:
1 - 3 of 3
BioCentury | Oct 15, 2012
Clinical News

Herceptin trastuzumab: Phase III data

Genentech Inc. , South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan F. Hoffmann-La Roche Ltd. (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Herceptin trastuzumab ( RG597 ) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2)...
BioCentury | Sep 27, 2004
Company News

Inyx, Phares Technology BV deal

...IYXI completed its acquisition of a platform technology from Phares subsidiary Phares Drug Delivery AG (Muttenz, Switzerland) that IYXI...
...substances to mucosal membranes. Financial terms were not disclosed. Inyx Inc. (IYXI), New York, N.Y. Phares...
BioCentury | May 6, 2002
Emerging Company Profile

Corporate Profile

...by Sanjay Kakkar, Canasta Group Ltd. and Thrombosis Research Institute Corporate partners: Covance Inc. , Phares...
Items per page:
1 - 3 of 3